Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.

Lauren W VeltriDenái R MiltonRuby DelgadoNina ShahKrina PatelYago NietoPartow KebriaeiUday R PopatSimrit ParmarBetül OranStefan CiureaChitra HosingHans C LeeElisabet ManasanchRobert Z OrlowskiElizabeth J ShpallRichard E ChamplinMuzaffar H QazilbashQaiser Bashir

Published in: Cancer (2017)

The current findings indicate that auto-HCT is an effective and safe therapy in patients with refractory multiple myeloma, including those who are refractory to IMiDs and PIs. Cancer 2017;123:3568-75. © 2017 American Cancer Society.

Keyphrases

multiple myeloma
papillary thyroid
squamous cell
stem cells
lymph node metastasis
childhood cancer
cell death
cell cycle arrest
replacement therapy